Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vincent Medical Holdings Limited ( (HK:1612) ) has issued an update.
Vincent Medical Holdings Limited reported its strongest interim results in four years for the six months ending June 30, 2025, with an 18.1% increase in revenue to HK$449.4 million and a 55.1% rise in profit attributable to owners, reaching HK$51.6 million. The impressive performance was mainly driven by a 28.6% surge in revenue from the imaging disposable products segment, alongside resumed growth in the respiratory products segment, which compensated for the decline in the orthopaedic and rehabilitation segment. The company’s gross profit increased by 33.4% due to economies of scale and improved operating efficiency, resulting in a gross profit margin improvement from 31.3% to 35.4%. The board declared an interim dividend of HK2.4 cents per share, reflecting the company’s robust financial health and commitment to its dividend policy.
The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.
More about Vincent Medical Holdings Limited
Vincent Medical Holdings Limited, incorporated in the Cayman Islands, operates in the medical device industry. The company focuses on the production and distribution of imaging disposable products, respiratory products, and orthopaedic and rehabilitation products.
Average Trading Volume: 1,741,000
Technical Sentiment Signal: Buy
Current Market Cap: HK$594.5M
Learn more about 1612 stock on TipRanks’ Stock Analysis page.